CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤中 BiTE 疗法所致 T 细胞耗竭：通过无治疗间期降低感染风险
英文原题：T-cell exhaustion due to BiTE therapy in multiple myeloma: mitigating infectious risks through treatment-free intervals.
查看英文原题
T-cell exhaustion due to BiTE therapy in multiple myeloma: mitigating infectious risks through treatment-free intervals.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）是一种目前可治疗但尚无法治愈的血液系统恶性肿瘤，患者一生中通常需要持续监测和治疗。包括一次性输注嵌合抗原受体（CAR）T细胞疗法在内的新型治疗，正在挑战持续治疗的传统模式。与既往标准疗法相比，CAR-T 及双特异性T细胞衔接器（BiTE）疗法可诱导更深的应答，且应答者的疗效往往持久。然而，BiTE疗法尤其容易导致免疫抑制和感染，且目前获批用法通常是持续给药直至疾病进展，因此出现了在治疗中安排停药间歇期的思路。本综述介绍T细胞耗竭如何推动接受BiTE治疗的MM患者发生免疫抑制和感染，并讨论可能的应对方法，以改善患者管理。
展开英文摘要原文
Multiple Myeloma (MM), a highly treatable but thus far incurable hematologic malignancy, has required continuous monitoring and treatment throughout a patient's lifetime. Newer classes of therapies, such as chimeric antigen receptor (CAR) T-cell therapy which constitutes of a one-time infusion, have challenged the continuous treatment paradigm. Compared to previously known standard therapies, CAR T-cell therapy along with bispecific T-cell engager (BiTE) therapy have been observed to induce deeper responses that tend to be durable in responders.
However, the degree of immunosuppression and infection noted especially with BiTE therapies, currently approved for ongoing administration until progression of disease, has given rise to the idea of incorporating treatment-free intervals. This review describes T-cell exhaustion as a driver for immunosuppression and infection in patients with MM receiving BiTE therapy and discusses potential ways to overcome it to improve management of patients.
论文信息
- 作者
- Dean EA
- 单位
- Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Orange, CA, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2026
- 原文标识
- PubMed 41646858 · DOI 10.3389/fimmu.2026.1705345
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →